Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?
Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium.
Erwin
E
Dreesen
Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium.
Ann
A
Gils
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D016903:Drug Monitoring; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D016023:Integrins / Q000037:antagonists & inhibitors*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D016023:Integrins; D014409:Tumor Necrosis Factor-alpha; C071777:integrin alpha4beta7; C543529:vedolizumab